ライフサイエンスコーパス: extracutaneous

1 development of melanoma, both cutaneous and extracutaneous.

2 ceous gland (SG) hypertrophy, hair loss, and extracutaneous abnormalities including growth retardatio

3 be extensive, permanent, and associated with extracutaneous abnormalities.

4 BAFF level was not correlated directly with extracutaneous cGVHD response, although full cutaneous r

5 ioner with their symptoms and any associated extracutaneous clinical or laboratory findings that may

6 ve cutaneous plaque and tumor involvement to extracutaneous compartments of blood, lymph nodes, and v

7 elative risk for the development of specific extracutaneous complications and/or premature death.

8 -based data are now available on the risk of extracutaneous complications in each of the major epider

9 ar OS, 55% and 28%); and FMF presenting with extracutaneous disease (group C; n = 17; 5-year and 10-y

10 There is no evidence of extracutaneous disease at presentation and for 6 months

11 The presence of extracutaneous disease at presentation is the most impor

12 One hundred twelve patients with extracutaneous disease at presentation or with progressi

13 from diagnosis, the risk for progression to extracutaneous disease by initial extent of skin involve

14 es of disease are no longer significant once extracutaneous disease develops.

15 t 5 years, 21% of all patients had developed extracutaneous disease.

16 in which skin lesions no longer regress and extracutaneous dissemination often occurs.

17 important role for MEC in the physiology of extracutaneous epithelial tissues, including diverse muc

18 The Lamc2(jeb) mice display additional extracutaneous features such as loss of bone mineralizat

19 e also associated with increased odds of all extracutaneous infections (P < .0001), except recurrent

20 th contribute to susceptibility to warts and extracutaneous infections in children.

21 een childhood AD, atopic disease, warts, and extracutaneous infections suggest that barrier disruptio

22 is associated with increased risk of warts, extracutaneous infections, and other atopic diseases and

23 hout other atopic disease had higher odds of extracutaneous infections, including strep throat, other

24 h might predispose toward both cutaneous and extracutaneous infections.

25 of 7.6 months as compared with those without extracutaneous involvement (17 patients), who had a more

26 ch are the histiocytoid variant), (2) a rare extracutaneous manifestation of Sweet's syndrome with ca

27 Rare fatalities have been reported in extracutaneous manifestation.

28 Those with extracutaneous manifestations at presentation (11 patien

29 ollowed by Western blot testing, to diagnose extracutaneous manifestations of Lyme disease.

30 The high prevalence of extracutaneous manifestations, along with activation of

31 us, is characterized by cutaneous mucinosis, extracutaneous manifestations, and a monoclonal gammopat

32 ein and differs in severity of skin lesions, extracutaneous manifestations, and performance status.

33 systemic lupus in addition to cases without extracutaneous manifestations, targeted treatments for D

34 period than had been completed previously on extracutaneous MF.

35 full cutaneous responders exhibited improved extracutaneous organ response rates compared with skin n

36 ages, especially hair, as well as a range of extracutaneous pathologies.

37 Objective extracutaneous signs of Lyme disease did not develop in

38 ammalian host, and is primarily expressed in extracutaneous sites during murine infection.

39 on syndrome with aberrant mast cells (MC) at extracutaneous sites has been described in patients with

40 e after the dissemination of the organism to extracutaneous sites in subsequent stages of infection.

41 e from advanced lesions (cutaneous tumors or extracutaneous sites); none of 12 patch/plaque stage CTC

42 f noncontiguous anatomic sites or those with extracutaneous spread.

43 e mitogenesis, as well as lipid synthesis in extracutaneous tissues.

44 lliculotropic MF, extent of skin lesions and extracutaneous transformation were associated with reduc

45 ful biomarker of BRAFi-induced cutaneous and extracutaneous tumor formation.

46 nd molecular characterization of 73 skin and extracutaneous tumors in 31 patients who underwent BRAFi

47 PTCH mutations in several types of sporadic extracutaneous tumors.